Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial. (linkinghub.elsevier.com)

Authors: Motzer RJ … Schmidinger M Journal: The Lancet Published: 2026-08-12 DOI: https://doi.org/10.1016/S0140-6736(26)01089-5